Diltiazem (Cardizem)
What studies of Diltiazem (Cardizem) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for pain.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Diltiazem (Cardizem) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Diltiazem (Cardizem) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Pain1 study · 1 (few people) person took Diltiazem (Cardizem) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · At one-year follow-up (few people)
Pain improved.
The evidence is very uncertain about the effect of diltiazem (Cardizem) on pain in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- —
- Outcome
- significant reduction in frequency and intensity of chest pain
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Headache | 1 study |
All papers
- Endothelial Dysfunction in a Patient With Post-COVID-19 Syndrome and Mutation of the MTHFR Gene and Prothrombin II.2025 · case report · 1 in the study
Summary
This case report describes a 25-year-old Mexican woman with post-COVID-19 syndrome and chest pain and dyspnea. The report is a single case presentation. One patient was enrolled, started treatment, and was analysed. No comparison group, randomisation, or crossover was reported. Treatment included short-term prophylactic apixaban with low-dose aspirin; colchicine and indomethacin were also initiated; the final treatment consisted of folic acid and vitamin B complex supplementation, low-dose aspirin, bisoprolol, and trimetazidine for angina control. Isosorbide was discontinued due to severe headache, and diltiazem yielded no significant improvement. Treatment duration was not reported; follow-up was at one year. The recorded outcomes were clinical improvement with a reduction in the frequency and intensity of angina, and a significant reduction in frequency and intensity of chest pain. The authors state that at a one-year follow-up the patient showed clinical improvement. Apixaban was discontinued after discharge. The authors acknowledge the limitation of reporting a single case.